beta-amyloid

β-Amyloid (25-35) (Aβ25-35) 是一种阿尔茨海默氏淀粉样蛋白β肽的Aβ(25-35) 片段，在培养细胞中显示出神经毒性作用。

β-Amyloid (31-35) (β-Amyloid 31-35) 是一种天然 Amyloid-β 肽的最短序列，具有神经毒性。

β-Amyloid 15-21 acetate (Beta-Amyloid(15-21) acetate) 是 Amyloid-β 肽的片段，可用于神经系统疾病的研究。该片段参与β折叠形成。

β-Amyloid (1-37) (human) 与阿尔茨海默病的精神状态有潜在关联。

The amyloid β-protein is a 39- to 43-amino acid polypeptide that is the primary constituent of senile plaques and cerebrovascular deposits in Alzheimer's disease and Down's syndrome. Additionally it acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro.

β-Amyloid (1-28), a fragment of the β-Amyloid protein, is involved in metal binding.

Amyloid β-peptide fragment; minimum section required to bind to brain proteins. Binds with high affinity to α7-nicotinic ACh receptors, and impairs memory retention following central administration in mice in vivo.

β-Amyloid (1-16) is an amyloidogenic protein fragment with a sequence derived from β-amyloid. It exhibits the ability to bind to metal ions, indicating its involvement in metal-binding processes. β-Amyloid, a peptide, is responsible for the formation of amyloid plaques in the brains of individuals affected by Alzheimer's disease (AD).

β-Amyloid (1-15) (Amyloid β-Protein (1-15)) 是 β-淀粉样蛋白片段，可用于研究阿尔茨海默病。

Rat form of the beta-Amyloid (1-40) peptide

Antibodies corresponding to beta-amyloid (4-10) are effective in vivo inhibitors of cytotoxicity, amyloid plaque formation and special memory disturbances in mice. This peptide does not elicit an inflammatory response.

This synthetic peptide consists of amino acids 22 to 40 of beta amyloid protein. This peptide sequence is often used in beta amyloid structure and aggregation studies.

β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.

This is a fragment of beta-amyloid peptide. It has amino acids 1 through 34.

Intracerebroventricular administration of synthetic peptides Beta-amyloid (12-20), (12-28), and (18-28) causes amnesia in mice. These peptides have only amino acid residues VFF at position 18 to 20 in common, suggesting the amnestic effect of the triad.

This is an N-terminal fragment of beta amyloid. It consists of amino acid residues 1 to 9. Truncated beta amyloid peptide (10-40) still forms amyloid fibrils and shows fibril polymorphism.

β-Amyloid (11-22) is a peptide fragment of β-Amyloid. Beta-amyloid peptide (Abeta), the primary component of amyloid plaques in the brains of Alzheimer’s patients, is believed to be the cause of Alzheimer’s Disease (AD), the most common neurodegenerative disorder.

β-Amyloid (13-27) is a synthetic peptide comprising amino acids 26 to 40 of the beta amyloid protein. It is utilized to study the kinetics of beta amyloid formation.

β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.

Anionic interaction of Beta-amyloid (1-11) with Factor XII is suspected to cause massive activation of the C4 (complement 4) system in the cerebrospinal fluid of Alzheimer's disease patients.

β-amyloid (12-28) TFA, a peptide fragment of β-amyloid protein (β1-42), is the major component of senile plaque cores. β-amyloid (12-28) has aggregation properties and the potential for Alzheimer's disease research.

Human beta-amyloid protein 42 (1-7) is a bioactive chemical.

β-Amyloid (22-35) is a 14-aa peptide, shows aggregates and induces neurotoxicity in the hippocampal cells. Beta amyloid (22-35) is a synthetic truncated fragment of beta-amyloid peptide.

β-Amyloid (29-40), a fragment of the Amyloid-β peptide, possesses physical and chemical properties similar to those of viral protein fusion peptides. The C-terminal fragments (29-40 42) of Alzheimer's beta amyloid peptide can induce the fusion of liposomes.